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Objectives. To analyze the patterns and risk factors of HIV drug resistance mutations among patients failing second-line treat-
ment and to describe early treatment responses to recommended third-line antiretroviral therapy (ART) in a national referral HIV 
clinic in Zimbabwe.
Methods. Patients on boosted protease inhibitor (PI) regimens for more than 6 months with treatment failure confirmed by 
2 viral load (VL) tests >1000 copies/mL were genotyped, and susceptibility to available antiretroviral drugs was estimated by the 
Stanford HIVdb program. Risk factors for major PI resistance were assessed by logistic regression. Third-line treatment was provided 
as Darunavir/r, Raltegravir, or Dolutegravir and Zidovudine, Abacavir Lamivudine, or Tenofovir.
Results. Genotypes were performed on 86 patients who had good adherence to treatment. The median duration of first- and 
second-line ART was 3.8 years (interquartile range [IQR], 2.3–5.1) and 2.6 years (IQR, 1.6–4.9), respectively. The median HIV viral 
load and CD4 cell count were 65 210 copies/mL (IQR, 8728–208 920 copies/mL) and 201 cells/mm
3 (IQR, 49–333 cells/mm3). Major 
PI resistance-associated mutations (RAMs) were demonstrated in 44 (51%) non-nucleoside reverse transcriptase inhibitor RAMs in 
72 patients (83%) and nucleoside reverse transcriptase inhibitors RAMs in 62 patients (72%). PI resistance was associated with age 
>24 years (P = .003) and CD4 cell count <200 cells/mm3 (P = .007). In multivariable analysis, only age >24 years was significantly 
associated (adjusted odds ratio, 4.75; 95% confidence interval, 1.69–13.38; P = .003) with major PI mutations. Third-line DRV/r- and 
InSTI-based therapy achieved virologic suppression in 29/36 patients (81%) after 6 months.
Conclusions. The prevelance of PI mutations was high. Adolescents and young adults had a lower risk of acquiring major PI 
resistance mutations, possibly due to poor adherence to ART. Third-line treatment with a regimen of Darunavir/r, Raltegravir/
Dolutegravir, and optimized nucleoside reverse transcriptase inhibitors was effective.
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The many benefits of combination antiretroviral therapy (ART) 
may be compromised by virologic failure and drug resistance 
[1]. ART programs in countries hard hit by the HIV pandemic 
in Sub-Saharan Africa are facing increasing virologic failure 
of firstline ART and high levels of drug resistance to non-nu-
cleoside reverse transcriptase inhibitors (NNRTIs) [2]. The 
emergence of resistance to ART is a consequence of expanded 
access to treatment and longer duration of ART exposure. To 
maintain the benefits of ART, international guidelines recom-
mend switching to second-line, boosted protease inhibitor 
(PI)–based ART to maintain virologic suppression [3]. Routine 
HIV viral load monitoring is essential for the early diagnosis 
of ART treatment failure [4]. In contrast to patients failing 
firstline NNRTI- and nucleoside reverse transcriptase inhib-
itor (NRTI)–based ART, the majority of patients failing with 
a PI-based second-line ART regimen do not acquire major PI 
resistance-associated mutations [5, 6].
As more people with suboptimal adherence are on ART, the 
number of patients failing first- and second-line ART regimens 
is increasing, and an increase in multiclass drug resistance is 
expected [7]. Ongoing success of ART programs will require 
an understanding of the emergence and patterns of HIV drug 
resistance among individuals in whom treatment has failed. 
Virologic failure occurs for multiple reasons, including subop-
timal adherence and drug intolerance/toxicity leading to drug 
resistance. After second-line failure, evidence of multiclass 
resistance following exposure to boosted PI regimens requires 
treatment with at least 2 fully active antiretroviral drugs to sup-
press viremia, reduce the transmission of resistant virus, and 
optimize the effectiveness of third-line ART. Several factors, 
such as the duration of PI use and viral load, have been iden-
tified as risk factors for developing PI resistance mutations [8]. 
Modeling provides evidence that genotyping to optimize third-
line ART is more cost-effective than switching patients failing 
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second-line to third-line based only on virologic failure [9]. 
In the Zimbabwe National ART program, boosted darunavir, 
recycling available nucleoside/nucleotide reverse transcriptase 
inhibitors, and an integrase strand transfer inhibitor (InSTI) are 
provided, as recommended by the World Health Organization 
(WHO) [3]. However, identification of multiclass drug resist-
ance and eligibility for third-line therapy requires genotypic 
resistance testing (GRT). For patients who have developed mul-
ticlass resistance to NNRTI, NRTIs, and boosted PIs, InSTIs 
have been approved as a new class of ART with a high barrier to 
resistance and an exceptional safety profile [10]. While recently 
approved in Botswana for firstline treatment, InSTIs are cur-
rently reserved for patients with evidence of multiclass resist-
ance in most resource-limited countries, including Zimbabwe. 
Darunavir, a second-generation protease inhibitor, has been 
shown to be effective against HIV resistant to Atazanavir and 
Lopinavir, and hence is a useful third-line option [11, 12]. 
Third-line treatment should include new drugs with a mini-
mum risk of cross-resistance to previously used regimens that 
are available in resource-limited settings [13].
In this study, we analyzed the patterns of HIV drug resistance 
mutations among patients failing second-line treatment and the 
risk factors for acquiring major PI resistance. We further describe 
early treatment responses to recommended third-line ART in an 
HIV clinic in Zimbabwe. Our broad aim was to inform planning 
for third-line ART programs in sub-Saharan Africa.
MATERIALS AND METHODS
Study Setting and ART Treatment Guidelines
Newlands Clinic is an HIV treatment center in Harare, 
Zimbabwe, that is a national referral site for patients who are 
supposed to start third-line ART treatment after second-line 
virologic failure. Firstline regimens comprise 2 nucleoside/
NRTIs—among them tenofovir (TDF), zidovudine (ZDV), 
abacavir (ABC), and lamivudine (3TC), and an NNRTI, either 
efavirenz (EFV) or nevirapine (NVP). Until 2013, stavudine 
(D4T) was part of the national firstline ART regimen. Second-
line regimens include 2 NRTIs and a ritonavir-boosted PI, 
either atazanavir or lopinavir. The NRTIs used in second-line 
are 3TC and AZT or TDF or ABC, depending on what the 
patient received for firstline treatment. Protease inhibitor mon-
otherapy is not part of national guidelines, and none of the 
patients studied received it. National guidelines recommend a 
change to a third-line regimen if virologic failure (2 consecutive 
HIV RNA tests >1000 copies/mL) occurs after at least 6 months 
of therapy and adherence is estimated to be greater than 95% 
by pill counts and/or pharmacy refill records [14]. National 
guidelines recommend that patients on second-line ART have 
at least 1 viral load test done per year. Patients with an elevated 
VL (>1000 copies/mL) must have a repeat test done 3 months 
after adherence support. At Newlands Clinic only, patients who 
are deemed adherent (assessed by pill counts) after an intensive 
adherence support program and who have acquired major PI 
resistance mutations are commenced on third-line ART. Third-
line regimens consist of Darunavir/ritonavir, Raltegravir or 
Dolutegravir, and an (optimized) NRTI based on GRT.
Enhanced Adherence Support Program
All patients suspected of second-line ART failure, that is, patients 
who had a VL >1000 copies/mL, were enrolled in a 6-week 
enhanced adherence support program before GRT between 
August 1, 2013, and July 31, 2016. Patients who had elevated viral 
loads met in support groups of 8–10 participants once weekly for 
approximately 2.5 hours. Group cognitive behavioral counseling 
was aimed at discussion of HIV and ART, the identification of 
barriers and challenges to adherence, and the strengthening 
of medication adherence. These meetings were facilitated by 
trained counselors. There were separate groups for participants 
age 24 years and younger and for those older than age 24 years. 
All patients had the VL test repeated after the adherence support 
program. HIV-1 viral load was measured by the Roche COBAS 
Ampliprep/COBAS Taqman HIV-1 Test, version 2.0.
ART Resistance Testing
GRT was done for patients suspected of second-line failure 
with a confirmed viral load >1000 copies/mL after 6 weeks of 
enhanced adherence support, and had good adherence, as per 
national guidelines. GRT was not done in patients who still had 
confirmed poor adherence after adherence support. Patients 
with poor adherence continued to receive adherence sup-
port, and repeated viral load tests were done every 3 months. 
Plasma viral RNA was extracted, reverse transcribed, and 
1.3 kb of the HIV-1 protease and reverse transcriptase genes 
was amplified as described by Manasa [15]. Amplicons were 
sequenced at MCLab Molecular Cloning Laboratories (http://
www.mclab.com), San Francisco, California. The chromato-
grams were assembled using Geneious software, version 8 
(http://www.geneious.com) [16], and consensus sequences 
were analyzed using the Stanford University HIV Drug 
Resistance Database’s HIVdb program, version 8.3 (https://
hivdb.stanford.edu/hivdb/by-sequences) [17]. The estimated 
level of resistance to ART was determined by the genotypic 
susceptibility scores (GSS) associated with each of the drug 
resistance mutations. The estimated level of resistance was 
calculated as follows: susceptible (total score 0–9), poten-
tial low-level resistance (total score 10–14), low-level resist-
ance (total score 15–29), intermediate resistance (total score 
30–59), and high-level resistance (total score of 60 and above).
Data Analysis
We analyzed the clinical data that were routinely collected for 
each patient. We used univariable and multivariable logistic 
regression to study the association between explanatory varia-
bles with the development of at least 1 major PI resistance-asso-
ciated mutation (RAM). We included the following explanatory 
variables: age (≤24 and >24 years according to the WHO, which 
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defines adolescents and young adults as people aged ≤24 years 
[18]), HIV RNA (≤100 000 and >100 000 copies/mL), sex, CD4 
cell count (≤200 and >200 cells/mm3), and duration of sec-
ond-line therapy (≤2 and >2 years). All variables were retained 
in multivariable logistic regression regardless of association in 
univariable analysis. Statistical tests were 2-sided, with a signif-
icance level of .05. There were no missing values. All statisti-
cal analyses were performed in Stata, version 13.0 (StataCorp, 
College Station, TX).
Ethics
The study was approved by the Medical Research Council 
of Zimbabwe (approval No. MRCZ/A/1336). Patients pro-
vided written informed consent before being enrolled into the 
enhanced adherence support program.
RESULTS
A total of 186 participants received adherence support for sec-
ond-line failure, 61 achieved postadherence support viral loads 
of less than 1000 copies/mL, 3 were lost to follow-up, 1 was 
transferred out, and 35 did not meet clinical criteria for geno-
typing due to confirmed poor adherence.
Of the 86 who were genotyped, 41 (48%) were female. Thirty-
six (42%) had initiated firstline ART at Newlands Clinic and 
had been switched to a second-line regimen after failing first-
line ART, and 50 patients (58%) were referred to Newlands 
Clinic, receiving second-line ART. The median age at geno-
typing was 27.7 years (IQR, 19.7–42.3 years). The median HIV 
viral load and CD4 cell count at the time of genotyping were 
65  210 copies/mL (IQR, 8728–208  920 copies/mL) and 201 
cells/mm3 (IQR, 49–333 cells/mm3), respectively. Participants 
had received firstline ART for a median of 3.8 years (IQR, 2.3–
5.1 years) and second-line ART for a median of 2.6 years (IQR, 
1.6–4.9 years). Participants had received a median of 6 (IQR, 
6–7) antiretroviral medicines for first- and second-line ART. 
Table 1 summarizes participant demographic and clinical char-
acteristics at the time of GRT. There were differences in educa-
tion level (P = .006), CD4 cell counts (P = .032), HIV viral load 
(P = .039), and marital status (P = .001) between patients who 
had PI RAMs and those without. Only 2 participants received 
ART for the prevention of mother-to-child transmission; both 
had received single-dose nevirapine.
Drug Resistance–Associated Mutations
Sanger sequencing was successful for all 86 patients. All patients 
had subtype C virus. Wild-type virus was found in 12 (14%) 
participants, and 74 (86%) had mutant virus. Most (n  =  72, 
83%) had at least 1 NNRTI RAM, as summarized in Figure 1. 
The most common NNRTI mutation was K103N (n = 30, 35%), 
followed by Y181C (n = 26, 32%) and G190 (n = 24, 28%).
Sixty-two participants (72%) had at least 1 NRTI RAM. The 
distribution of major NRTI mutations is summarized in Figures 
1 and 2. Two-thirds had the NRTI mutation M184V (n = 58, 
67%), followed by the thymidine analogue mutations T215Y 
(n  =  31, 36%) and D67N (n  =  31, 36%). Overall, 13 (15%) 
patients had the K65R mutation, which confers high-level 
resistance to Tenofovir. All 13 patients with the K65R mutation 
had been exposed to TDF for either first- or second-line ART. 
Table 1. Sociodemographic, Clinical, and Biological Characteristics of Study Population With HIV-1 Sequences (n = 86) Comparing Those With and 
Without PI Mutations
Parameter
All Patients
(n = 86) No PI Mutation (n = 42) Any PI Mutation (n = 44) P Value
Median age (IQR), y 27.7 (19.7–42.3) 21.2 (18.0–38.3) 37.4 (25.9–46.9) .004
Gender, n (%)
Female 41 (47.7) 22 (52.4) 19 (43.2) .729
Marital status, n (%)
Single 47 (54.7) 32 (76.2) 15 (34.1) .001
Married 30 (34.9) 7 (11.7) 23 (52.3)
Widowed 7 (8.1) 3 (7.1) 4 (9.1)
Divorced 2 (2.3) 0 (0) 2 (4.6)
Level of Education
None 12 (14)  9 (21.4)  3 (6.8) .006
Primary 17 (19.7) 12 (28.6)  5 (11.4)
Secondary 43 (50) 18 (42.9) 25 (56.8)
Tertiary 14 (16.3)  3 (7.1) 11 (25)
Clinical
CD4 count, median (IQR), cell/mm3 201 (49–333) 243 (132–379) 97 (22–277) .032
HIV RNA, median (IQR), copies/mL 65 210 (8728–208 920) 37 238 (4620–147 592) 79 362 (20 376–254 612) .039
Duration of ART (IQR), y 7.7 (5.3–9.4) 7.3 (5.0–9.4) 7.9 (6.1–9.5) .388
2nd-line ART duration (IQR), y 2.6 (1.6–4.9) 2.4 (1.6–4.7) 2.6 (1.7–5.2) .318
No. of ART drugs received, median (IQR) at GRT 6 (6–7) 6.5 (6–8) 6 (5–7) .081
Abbreviations: GRT, genotypic resistance testing; PI, protease inhibitor; RAM, resistance-associated mutation. 
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At the time of GRT, of the patients with the K65R mutation, 
4  were receiving TDF/3TC, 2 AZT/3TC, and 7 ABC/3TC, as 
the NRTI backbone for second-line treatment. The multidrug 
NRTI drug resistance mutations T69Ins and Q151M were pres-
ent in 7 (8%) and 4 (5%) participants, respectively. Overall, 46 
(54%) had at least 1 thymidine analogue mutation (TAM), and 
25 (30%) had 3 or more TAMs. Figure 1 highlights the observed 
frequency of TAMs among the participants; 66 (76.7%) partici-
pants had pathway 2 TAMs [19].
PI RAMs were present in 50 (58%) participants, and major 
PI RAMs were present in 44 (51%) participants. Figures 1 and 
2 summarize the frequency of major PI mutations and the 
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Figure 2. Distribution of specific HIV drug resistance mutations. Abbreviation: HIVDR, HIV drug resistance.
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number of major PI mutations per patient. The most common 
PI mutation was M46I (n = 28, 33%), followed by I50V (n = 18, 
21%) and V82A (n = 18, 21%). A total of 24 participants (28%) 
had at least 3 major PI RAMs.
Figure  3 highlights the results of estimated resistance for 
potential third-line ART drugs. The HIV drug resistance in-
terpretation for PI showed that 40 (48%) participants had a 
virus susceptible to atazanavir, 62 (74%) were fully susceptible 
to darunavir, and 44 (52%) were fully susceptible to lopinavir. 
For NNRTI, full susceptibility was predicted for 18 (21%) to 
nevirapine, 19 (23%) to efavirenz, 21 (25%) to etravirine, and 
19 (22%) to rilpivirine. For the NRTIs, full susceptibility to 
Lamivudine/Emtricitabine was noted in 26 (31%), to Abacavir 
or Didanosine was noted in 25 (30%), to Zidovudine was noted 
in 44 (51%), and to Tenofovir was noted in 35 (42%).
Risk Factors for PI Drug Resistance Mutations
Table  2 summarizes the risk factors for developing PI muta-
tions. In univariable analysis, participants who had a CD4 cell 
count of <200 cells/mm3 (odds ratio, 3.67 cells/mm3; 95% con-
fidence interval [CI], 1.43–9.43 cells/mm3) were more likely 
to have major PI mutations. Age >24 years was independently 
associated with the risk of having major PI mutations in mul-
tivariable analysis (adjusted odds ratio,  4.75  years; 95% CI, 
1.69–13.38  years). HIV viral load and CD4 cell count were 
not independently associated with the risk of having major 
PI mutations; neither was the duration of receiving PI-based 
second-line ART.
Early Third-Line Outcomes
The decision to switch to third-line ART was based on 
the presence of major PI RAMs conferring resistance to 
Atazanavir and Lopinavir. A total of 36 patients (19 females 
and 17 males) were commenced on a third-line ART regimen 
of darunavir, raltegravir, and optimized NRTI. Two patients 
with PI mutations continued on second-line (1 had very poor 
adherence due to psychiatric illness, and the other was receiv-
ing palliative care for disseminated cancer of the cervix), and 
6 patients died before commencing third-line ART. Figure 4 
highlights the outcomes of the patients who received third-
line therapy. The median age of patients at commencement of 
third-line therapy was 41 years (IQR, 30–47.5 years). Patients 
were severely immunosuppressed with a median CD4 cell 
count of 147.5 cells/mm3 (IQR, 28–252.5 cells/mm3) and a 
median HIV viral load of 57 774 copies/mL (IQR, 18 809–
215 624 copies/mL) at commencement of third-line therapy. 
At the time of analysis among participants commenced on 
third-line ART, none had been lost to follow-up and 2 had 
died, 1 due to chronic renal failure (diagnosed while the 
participant was on firstline therapy) and 1 due to acute alco-
hol-induced pancreatitis.
At week 24 on third-line therapy, the median CD4 cell count 
increased from 147.5 to 251.5 cells/mm3 (IQR, 187.5–381 cells/
mm3). At week 24 on third-line therapy, 29/36 (81%) partici-
pants achieved viral suppression of <50 copies/mL, 5/36 (14%) 
patients had VL between 50 and 1000 copies/mL and 1/36 (3%) 
had died. One, a 17-year-old adolescent, had a week 24 VL of 
2244 copies/mL and has been receiving adherence support, and 
to date he has not managed to achieve virological suppression. 
There were no reported discontinuations due to toxicity of any 
of the third-line medicines.
Among the 39 patients who had no PI mutations and con-
tinued on second-line ART with ongoing adherence sup-
port, only 8 achieved virological suppression 24 weeks after 
HIV drug resistance testing. Two participants were recom-
menced on firstline (because they had wild-type virus), 
and both achieved virological suppression after 24 weeks of 
firstline ART.
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DISCUSSION
Among patients referred for second-line failure and geno-
typed after 6 weeks of aggressive adherence support, 14% had 
wild-type virus, suggesting very low adherence, and 86% had 
mutant virus. Among those with drug resistance mutations, 
all had 1 or more NNRTI and/or NRTI mutations and 44/86 
(51%) had major PI resistance mutations. Younger patients 
(<24 years), were less likely to have acquired major PI drug 
resistance mutations upon failing PI-based second-line treat-
ment. Viral load and immunological status at resistance 
testing were not independently associated with major PI 
RAMs. Early third-line treatment outcomes were excellent, 
with 30/36 patients achieving viral loads <50 copies/mL at 
24 weeks.
86 participants
had GRT
42 had no major 
PI RAMs
44 had PI RAMs
39 continued 2nd-line
1 deceased
2 switched to 1st 36 received 3rd-line
6 deceased
2 continued 2nd
VL at 24 Weeks
30 had VL >1000 
1 had VL of 183 
8 had VL <50
24 Weeks outcome
1 had VL >1000
5 had VL 50–1000
29 had VL <50
1 died 
61 resuppressed
35 confirmed poor 
adherence
3 LTFU
1 transferred out
186 participants 
received EAC
Figure 4. Outcomes of patients failing second-line antiretroviral therapy who received genotypic resistance testing. Abbreviations: EAC, enhanced adherence counseling; 
GRT, genotypic resistance testing; LTFU, loss to follow-up; PI, protease inhibitor; RAM, resistance-associated mutation; VL, viral load. 
Table 2. Risk Factors for Major Protease Inhibitor Resistance Mutations
Univariable Multivariable
Risk Factor OR (95% CI) P Value OR (95% CI) P Value
VL > 100 000 copies/mL 2.04 (0.84–4.92) .114 2.14 (0.75–6.12) .155
2nd-line duration > 2 y 1.31 (0.5–3.14) .541 1.65 (0.61–4.50) .327
Age > 24 y 4.11 (1.62–10.43) .003 4.75 (1.69–13.34) .003
CD4 < 200 cells/mm3 3.67 (1.43–9.43) .007 2.53 (0.90–7.15) .079
Abbreviations: CI, confidence interval; OR, odds ratio; VL, viral load.
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This study has some limitations. Our sample size was small. 
However, as resistance data after second-line failure are scarce, 
we believe that these results are important to clinicians look-
ing after patients failing second-line ART. Population-based 
sequencing, used in this analysis, is not able to detect minority 
resistant viral strains, thus potentially underestimating resist-
ance [20]. Moreover, the durability of suppression on third-line 
therapy was only established for 6 months, and longer follow-up 
is essential. Lack of resistance patterns after firstline failure was 
also a limitation.
Patterns of DRM demonstrate that despite interventions to 
improve adherence, almost half of the patients who had GRT 
done did not acquire major PI resistance-associated mutations. 
A total of 61 (33%) patients out of the original 186 resuppressed 
after adherence support, highlighting that they had a virus sus-
ceptible to second-line ART. This provides evidence that viro-
logic failure is likely due to poor adherence, leading to reduced 
drug exposure. A  number of studies from resource-limited 
settings have reported low rates of PI resistance after failure of 
second-line ART [5, 6, 21], often attributing this finding to poor 
medication adherence. The presence of major protease inhibitor 
mutations at the time of second-line failure ranges from 0% to 
50% [22]. A  recent national survey in Kenya reported a 25% 
prevalence of PI mutations among patients failing second-line 
ART [23]. The high prevalence of PI resistance in our cohort 
can be attributed to possible selection bias. Only patients with 
reported good adherence (after at least 6 weeks of enhanced 
adherence counseling) had a GRT done, that is, only 86 out of 
the original 186. The association of younger age and PI resist-
ance is consistent with findings from similar studies in South 
Africa and the United Kingdom [5, 24, 25]. These studies show 
that second-line failure in young people is often due to poor 
adherence rather than development of PI RAMs. Age may pro-
vide an explanation for some of the patient-level, regimen-spe-
cific, and structural factors associated with the absence of PI 
mutations and reduced adherence to second-line ART [26–29]. 
Social and structural obstacles to adherence can include inac-
cessible clinic location or lack of access to transportation, work/
child care responsibilities, and low health care provider to 
patient ratio as a consequence of the rapid growth in ART roll-
out programs [30, 31]. Optimizing treatment adherence and 
retention at all stages in the cascade of HIV care is critical to the 
prevention of resistance.
As expected in Africa, the predominant NRTI mutation 
observed in our cohort was MI84V, which confers high-level 
resistance to Lamivudine and Emtricitabine [32]. The observed 
prevalence of TAMs was high, the commonest being T215Y and 
D67N. TAMs are known to accumulate in patients who remain 
on a failing ART regimen due to delays in detecting treatment 
failure [33]. Patients may have been failing on second-line ART 
for a long time before enrolling in the adherence program, but 
either viral loads were not done prior to that time or the data 
were not provided. It is important for HIV treatment programs 
to offer routine viral load testing to enable early diagnosis of 
treatment failure and hence prevent accumulation of TAMs. 
TAMs have the potential to confer resistance to all drugs in the 
NRTI class.
Despite the absence of NNRTI exposure during second-line 
ART, the virus from almost 84% of patients had at least 1 major 
NNRTI resistance mutation, and the virus from 40% had a 
mutation at the K103N codon, strongly associated with resist-
ance to nevirapine and efavirenz. The persistence of NNRTI 
resistance is consistent with genotypic analyses of 2 South 
African cohorts that failed PI-based ART [5, 25] and precludes 
recycling of firstline NNRTI drugs in third-line therapy. The 
high levels of NNRTI resistance mutations may indicate exten-
sive drug resistance including NRTI mutations prior to the 
onset of second-line therapy.
The need for evidence regarding the implementation of third-
line ART in resource-limited settings has been recognized by the 
WHO [3]. Our data demonstrate the effectiveness of third-line 
ART in a cohort of patients who are infected with HIV subtype 
C. The majority of patients achieved virologic suppression on 
regimens including darunavir/ritonavir, raltegravir, and NRTIs, 
suggesting that this can be used as a standardized third-line reg-
imen in Zimbabwe. Data on the treatment outcomes of third-
line ART are still very scarce in sub-Saharan Africa; however, 2 
other reports have provided evidence of effectiveness [34, 35]. 
In a small Indian cohort, early treatment outcomes showed 
excellent effectiveness of third-line ART [36]. Although the 
small cohort size limits wider assumptions of efficacy, the pre-
liminary outcomes suggest that third-line therapy can be effect-
ively implemented in a resource-limited setting with excellent 
rates of virologic suppression. Furthermore, our results support 
the use of darunavir/ritonavir and an InSTI backbone for third-
line ART, as recommended by the WHO [3].
CONCLUSIONS
Prevalence of RAMs was high among participants failing sec-
ond-line ART. However, only half of these participants had 
major PI RAMs, which necessitate the switch to third-line 
treatment. The presence of major PI RAMs was significantly 
associated with an increase in age. Younger participants were 
more likely to fail second-line treatment due to poor adherence 
rather than development of PI resistance. GRT is essential to 
identify those with triple class resistance, and those who require 
third-line therapy to regain and sustain virologic suppression. 
A  Darunavir/r, Integrase strand transfer inhibitor and opti-
mized NRTI (based on GRT) regimen was effective in achieving 
virologic suppression in early follow-up. Our results show that 
third-line regimens for patients with multidrug-resistant HIV 
in Africa are likely to be effective.
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